{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:15:50Z","timestamp":1794629750786,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fudan University Huashan Hospital Basic Research Cultivation Program","award":["2024JC057"],"award-info":[{"award-number":["2024JC057"]}]},{"name":"Shanghai Shenkang Clinical Innovation Project","award":["SHDC12020112"],"award-info":[{"award-number":["SHDC12020112"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06749-z","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:44:35Z","timestamp":1772001875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Superiority of high-dose cytarabine\u2013based mobilisation over cyclophosphamide or plerixafor in primary CNS lymphoma"],"prefix":"10.1007","volume":"105","author":[{"given":"Qing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"6749_CR1","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1182\/bloodadvances.2023011657","volume":"8","author":"TT Batchelor","year":"2024","unstructured":"Batchelor TT, Giri S, Ruppert AS et al (2024) Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101. Blood Adv 8:3189\u20133199. https:\/\/doi.org\/10.1182\/bloodadvances.2023011657","journal-title":"Blood Adv"},{"key":"6749_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/17474086.2022.2018297","volume":"15","author":"S Steffanoni","year":"2022","unstructured":"Steffanoni S, Calimeri T, Anzalone N et al (2022) A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma. Expert Rev Hematol 15:33\u201343. https:\/\/doi.org\/10.1080\/17474086.2022.2018297","journal-title":"Expert Rev Hematol"},{"key":"6749_CR3","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1093\/neuonc\/noae115","volume":"26","author":"KR Tringale","year":"2024","unstructured":"Tringale KR, Scordo M, Yahalom J et al (2024) Outcomes and relapse patterns in primary central nervous system lymphoma: longitudinal analysis of 559 patients diagnosed from 1983 to 2020. Neuro Oncol 26:2061\u20132073. https:\/\/doi.org\/10.1093\/neuonc\/noae115","journal-title":"Neuro Oncol"},{"key":"6749_CR4","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/bloodadvances.2024012760","volume":"8","author":"AM Bock","year":"2024","unstructured":"Bock AM, Mwangi R, Wang Y et al (2024) Defining primary refractory large B-cell lymphoma. Blood Adv 8:3402\u20133415. https:\/\/doi.org\/10.1182\/bloodadvances.2024012760","journal-title":"Blood Adv"},{"key":"6749_CR5","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1182\/blood-2015-10-636340","volume":"127","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Illerhaus G (2016) The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood 127:1642\u20131649. https:\/\/doi.org\/10.1182\/blood-2015-10-636340","journal-title":"Blood"},{"key":"6749_CR6","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1016\/j.clml.2018.11.018","volume":"19","author":"I Alnahhas","year":"2019","unstructured":"Alnahhas I, Jawish M, Alsawas M et al (2019) Autologous stem-cell transplantation for primary central nervous system lymphoma: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk 19:e129\u2013e141. https:\/\/doi.org\/10.1016\/j.clml.2018.11.018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6749_CR7","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1016\/s2352-3026(16)30050-3","volume":"3","author":"G Illerhaus","year":"2016","unstructured":"Illerhaus G, Kasenda B, Ihorst G et al (2016) High-dose chemotherapy with autologous Haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol 3:e388\u2013e397. https:\/\/doi.org\/10.1016\/s2352-3026(16)30050-3","journal-title":"Lancet Haematol"},{"key":"6749_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/jco.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S et al (2019) Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS randomized phase II precis study. J Clin Oncol 37:823\u2013833. https:\/\/doi.org\/10.1200\/jco.18.00306","journal-title":"J Clin Oncol"},{"key":"6749_CR9","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM et al (2015) R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 125:1403\u201310. https:\/\/doi.org\/10.1182\/blood-2014-10-604561","journal-title":"Blood"},{"key":"6749_CR10","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/bloodadvances.2022007497","volume":"7","author":"CLE Hazenberg","year":"2023","unstructured":"Hazenberg CLE, Graaf AO, Mulder R et al (2023) Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study. Blood Adv 7:1269\u20131278. https:\/\/doi.org\/10.1182\/bloodadvances.2022007497","journal-title":"Blood Adv"},{"key":"6749_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/bjh.17316","volume":"193","author":"G Gifford","year":"2021","unstructured":"Gifford G, Hesson L, Wong JWH et al (2021) Poor mobilization of autologous CD34(+) peripheral blood stem cells in haematology patients undergoing autologous stem cell transplantation is associated with the presence of variants in genes implicated in clonal haematopoiesis of indeterminant potential. Br J Haematol 193:841\u2013844. https:\/\/doi.org\/10.1111\/bjh.17316","journal-title":"Br J Haematol"},{"key":"6749_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-02802-6","volume":"13","author":"C Luo","year":"2022","unstructured":"Luo C, Wu G, Huang X et al (2022) Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials. Stem Cell Res Ther 13:123. https:\/\/doi.org\/10.1186\/s13287-022-02802-6","journal-title":"Stem Cell Res Ther"},{"key":"6749_CR13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","volume":"14","author":"I Pusic","year":"2008","unstructured":"Pusic I, Jiang SY, Landua S et al (2008) Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 14:1045\u20131056. https:\/\/doi.org\/10.1016\/j.bbmt.2008.07.004","journal-title":"Biol Blood Marrow Transplant"},{"key":"6749_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","volume":"20","author":"S Giralt","year":"2014","unstructured":"Giralt S, Costa L, Schriber J et al (2014) Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 20:295\u2013308. https:\/\/doi.org\/10.1016\/j.bbmt.2013.10.013","journal-title":"Biol Blood Marrow Transplant"},{"key":"6749_CR15","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jcyt.2023.04.014","volume":"25","author":"P Ye","year":"2023","unstructured":"Ye P, Pei R, Lian J et al (2023) Higher efficacy of etoposide\u2009+\u2009cytarabine plus pegfilgrastim in poorly mobilizing multiple myeloma and lymphoma patients. Cytotherapy 25:885\u2013890. https:\/\/doi.org\/10.1016\/j.jcyt.2023.04.014","journal-title":"Cytotherapy"},{"key":"6749_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1439253","volume":"15","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Li X, Yuan X et al (2024) Efficacy and safety of stem cell mobilization with etoposide\u2009+\u2009cytarabine plus G-CSF in poor mobilizers with relapsed or refractory lymphoma. Front Immunol 15:1439253. https:\/\/doi.org\/10.3389\/fimmu.2024.1439253","journal-title":"Front Immunol"},{"key":"6749_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.29271\/jcpsp.2025.03.367","volume":"35","author":"I Hidayat","year":"2025","unstructured":"Hidayat I, Khan MA, Awan MN et al (2025) Stem cell mobilisation failure in auto HSCT and its factors: A single centre experience. J Coll Physicians Surg Pak 35:367\u2013371. https:\/\/doi.org\/10.29271\/jcpsp.2025.03.367","journal-title":"J Coll Physicians Surg Pak"},{"key":"6749_CR18","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/ijlh.14337","volume":"46","author":"L Ran","year":"2024","unstructured":"Ran L, Peng Y, Zhao M et al (2024) Predictive model of the efficiency of hematopoietic stem cell collection in patients with multiple myeloma and lymphoma based on multiple peripheral blood markers. Int J Lab Hematol 46:1068\u20131076. https:\/\/doi.org\/10.1111\/ijlh.14337","journal-title":"Int J Lab Hematol"},{"key":"6749_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2329140","volume":"56","author":"Y Li","year":"2024","unstructured":"Li Y, Qiu X, Lei Y, Zhou R (2024) G-CSF\u2009+\u2009plerixafor versus G-CSF alone mobilized hematopoietic stem cells in patients with multiple myeloma and lymphoma: a systematic review and meta-analysis. Ann Med 56:2329140. https:\/\/doi.org\/10.1080\/07853890.2024.2329140","journal-title":"Ann Med"},{"key":"6749_CR20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1159\/000531940","volume":"50","author":"E Jantunen","year":"2023","unstructured":"Jantunen E, Partanen A, Turunen A et al (2023) Mobilization strategies in myeloma patients intended for autologous hematopoietic cell transplantation. Transfus Med Hemother 50:438\u2013447. https:\/\/doi.org\/10.1159\/000531940","journal-title":"Transfus Med Hemother"},{"key":"6749_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/scd.2024.0178","volume":"34","author":"C Hochheuser","year":"2025","unstructured":"Hochheuser C, Rozeman ML, Kunze N et al (2025) PEGylated granulocyte colony-stimulating factor and plerixafor enhance autologous stem and progenitor cell mobilization and transplantation in pediatric patients. Stem Cells Dev 34:61\u201372. https:\/\/doi.org\/10.1089\/scd.2024.0178","journal-title":"Stem Cells Dev"},{"key":"6749_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2025.104096","volume":"64","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Xu S, Pei R et al (2025) Etoposide\u2009+\u2009cytarabine\u2009+\u2009pegfilgrastim versus cyclophosphamide\u2009+\u2009G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma. Transfus Apher Sci 64:104096. https:\/\/doi.org\/10.1016\/j.transci.2025.104096","journal-title":"Transfus Apher Sci"},{"key":"6749_CR23","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/trf.17829","volume":"64","author":"V Dill","year":"2024","unstructured":"Dill V, Blum P, Lindemann A et al (2024) Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: a single-center retrospective analysis. Transfusion 64:871\u2013880. https:\/\/doi.org\/10.1111\/trf.17829","journal-title":"Transfusion"},{"key":"6749_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01606-w","volume":"17","author":"M Alcantara","year":"2024","unstructured":"Alcantara M, Chevrier M, Jardin F et al (2024) Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB\/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients. J Hematol Oncol 17:86. https:\/\/doi.org\/10.1186\/s13045-024-01606-w","journal-title":"J Hematol Oncol"},{"key":"6749_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09723-w","volume":"22","author":"J Wendler","year":"2022","unstructured":"Wendler J, Fox CP, Valk E et al (2022) Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma. BMC Cancer 22:971. https:\/\/doi.org\/10.1186\/s12885-022-09723-w","journal-title":"BMC Cancer"},{"key":"6749_CR26","doi-asserted-by":"publisher","first-page":"115068","DOI":"10.1016\/j.ejca.2024.115068","volume":"213","author":"FA de Groot","year":"2024","unstructured":"de Groot FA, Dekker TJA, Doorduijn JK et al (2024) Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies. Eur J Cancer 213:115068. https:\/\/doi.org\/10.1016\/j.ejca.2024.115068","journal-title":"Eur J Cancer"},{"key":"6749_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01213","volume":"10","author":"X Zheng","year":"2020","unstructured":"Zheng X, Yang S, Chen F et al (2020) The efficacy and safety of cytarabine on newly diagnosed primary central nervous system lymphoma: a systematic review and meta-analysis. Front Oncol 10:1213. https:\/\/doi.org\/10.3389\/fonc.2020.01213","journal-title":"Front Oncol"},{"key":"6749_CR28","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","volume":"36","author":"AJM Ferreri","year":"2022","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E et al (2022) Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia 36:1870\u20131878. https:\/\/doi.org\/10.1038\/s41375-022-01582-5","journal-title":"Leukemia"},{"key":"6749_CR29","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/s2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E et al (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol 4:e510\u2013e523. https:\/\/doi.org\/10.1016\/s2352-3026(17)30174-6","journal-title":"Lancet Haematol"},{"key":"6749_CR30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/trf.12906","volume":"55","author":"C Calder\u00f3n-Cabrera","year":"2015","unstructured":"Calder\u00f3n-Cabrera C, Gonz\u00e1lez MC, Mart\u00edn J et al (2015) Intermediate doses of cytarabine plus granulocyte-colony-stimulating factor as an effective and safe regimen for hematopoietic stem cell collection in lymphoma patients with prior mobilization failure. Transfusion 55:875\u20139. https:\/\/doi.org\/10.1111\/trf.12906","journal-title":"Transfusion"},{"key":"6749_CR31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/bmt.2012.269","volume":"48","author":"S Giebel","year":"2013","unstructured":"Giebel S, Kruzel T, Czerw T et al (2013) Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers. Bone Marrow Transplant 48:915\u201321. https:\/\/doi.org\/10.1038\/bmt.2012.269","journal-title":"Bone Marrow Transplant"},{"key":"6749_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.825550","volume":"12","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, Li X, Liu Y et al (2022) High efficacy of stem cell mobilization with etoposide\u2009+\u2009cytarabine plus G-CSF in patients with multiple myeloma. Front Oncol 12:825550. https:\/\/doi.org\/10.3389\/fonc.2022.825550","journal-title":"Front Oncol"},{"key":"6749_CR33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.htct.2023.08.007","volume":"46","author":"KJS de Andrade","year":"2024","unstructured":"de Andrade KJS, Botelho LFB, Calixto RF et al (2024) Evaluation of efficacy and safety in the use of cytarabine for mobilization of hematopoietic stem cells in a reference hospital in Northeastern Brazil. Hematol Transfus Cell Ther 46:428\u2013433. https:\/\/doi.org\/10.1016\/j.htct.2023.08.007","journal-title":"Hematol Transfus Cell Ther"},{"key":"6749_CR34","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/cncr.29023","volume":"121","author":"YB Chen","year":"2015","unstructured":"Chen YB, Batchelor T, Li S et al (2015) Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 121:226\u2013233. https:\/\/doi.org\/10.1002\/cncr.29023","journal-title":"Cancer"},{"key":"6749_CR35","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ajh.27685","volume":"100","author":"E Muchtar","year":"2025","unstructured":"Muchtar E, Sanchorawala V, Hassan H et al (2025) The impact of melphalan conditioning and CD34\u2009+\u2009cell dose and schedule on post-transplant outcomes in AL amyloidosis. Am J Hematol 100:1141\u20131151. https:\/\/doi.org\/10.1002\/ajh.27685","journal-title":"Am J Hematol"},{"key":"6749_CR36","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/bjh.14276","volume":"175","author":"MJ Watts","year":"2016","unstructured":"Watts MJ, Ings SJ, Balsa C et al (2016) Re-evaluation of progenitor thresholds and expectations for haematopoietic recovery based on an analysis of 810 autologous transplants: implications for quality assurance. Br J Haematol 175:673\u2013676. https:\/\/doi.org\/10.1111\/bjh.14276","journal-title":"Br J Haematol"},{"key":"6749_CR37","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ajh.25826","volume":"95","author":"E Maffini","year":"2020","unstructured":"Maffini E, Labopin M, Blaise D et al (2020) <article-title update=\"added\">CD34 + cell dose effects on clinical outcomes after T\u2010cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation ( EBMT ). Am J Hematol 95:892\u2013899. https:\/\/doi.org\/10.1002\/ajh.25826","journal-title":"Am J Hematol"},{"key":"6749_CR38","unstructured":"National Comprehensive Cancer Network (2025) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Central Nervous System Cancers. Version 3.2025 \u2014 December 5"},{"key":"6749_CR39","first-page":"794","volume":"88","author":"M Picardi","year":"2003","unstructured":"Picardi M, Rosa GD, Selleri C et al (2003) Spleen enlargement following Recombinant human granulocyte colony-stimulating factor administration for peripheral blood stem cell mobilization. Haematologica 88:794\u2013800","journal-title":"Haematologica"},{"key":"6749_CR40","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1182\/blood.v99.11.4228","volume":"99","author":"M Picardi","year":"2002","unstructured":"Picardi M, Martinelli V, Ciancia R et al (2002) Measurement of spleen volume by ultrasound scanning in patients with thrombocytosis: a prospective study. Blood 99:4228\u20134230. https:\/\/doi.org\/10.1182\/blood.v99.11.4228","journal-title":"Blood"},{"key":"6749_CR41","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.amjms.2024.07.031","volume":"369","author":"X Wang","year":"2025","unstructured":"Wang X, Guo W, Li J et al (2025) A retrospective study on the efficacy of pegfilgrastim-filgrastim combination regimen in the mobilization for autologous stem cell transplantation in lymphoma patients. Am J Med Sci 369:96\u2013104. https:\/\/doi.org\/10.1016\/j.amjms.2024.07.031","journal-title":"Am J Med Sci"},{"key":"6749_CR42","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1111\/bjh.19367","volume":"204","author":"P Ye","year":"2024","unstructured":"Ye P, Cheng Y, Lian J et al (2024) Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: A prospective multicentre study. Br J Haematol 204:2342\u20132350. https:\/\/doi.org\/10.1111\/bjh.19367","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06749-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06749-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06749-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:36Z","timestamp":1776405576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06749-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6749"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06749-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, local legislation, and institutional requirements, and was approved by the Ethics Committee of Huashan Hospital, Fudan University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}